SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) — Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Nextracker Inc. (NASDAQ: NXT). The lawsuit seeks to recover losses on behalf of investors who acquired securities between February 1, 2024 and August 1, 2024. Investors have until February 25, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit. If you incurred significant losses and want to act as the lead…
-
In this article 9987-HK Follow your favorite stocksCREATE FREE ACCOUNT Investors eyeing up firms with the potential to become the “blue chip…
-
TORONTO, Jan. 07, 2025 (GLOBE NEWSWIRE) — Currency Exchange International, Corp. (“CXI” or the “Company”) (TSX: CXI) (OTC: CURN), announced today that a Special Committee of independent directors is actively considering a range of strategic options for its wholly-owned subsidiary, Exchange Bank of Canada (“EBC”), a federally chartered non-deposit-taking Canadian Schedule I bank. The strategic review aims to explore opportunities to maximize long-term value for shareholders and focus the Company’s resources towards its profitable U.S. operations. The formal review of…
-
HOUSTON and LONDON, Jan. 07, 2025 (GLOBE NEWSWIRE) — LyondellBasell (NYSE: LYB), a leader in the global chemical industry, will announce its fourth-quarter 2024 financial results before the U.S. market opens Friday, Jan. 31, followed by a webcast and teleconference to discuss the results at 11 a.m. EST. Teleconference and webcast detailsFriday, Jan. 31, 202511 a.m. ESTHosted by David Kinney, head of investor relationsAccess the webcast 10 to 15 minutes prior to the start of the call at www.lyondellbasell.com/earnings. Toll-free teleconference…
-
Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectively More than 3,500 unique prescribers and over 16,000 prescriptions filled in 2024 across a broad COPD population Approximately 45% of Tier 1 HCPs prescribed Ohtuvayre LONDON and RALEIGH, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces preliminary unaudited net product sales for…
-
Shoji Morimoto’s day job involves loaning himself out to strangers who seek someone’s company for almost anything at all. Lee Ying Shan…
-
Primary endpoint of overall function (ALSFRS-R) and survival, and key secondary endpoints of muscle strength and respiratory function, were not met at 24 weeksOverall, DNL343 was found to be safe and well toleratedAdditional analyses, including neurofilament light (NfL) and other fluid biomarkers, prespecified sub-group analyses and analyses from the active treatment extension period are expected later in 2025 SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (NASDAQ: DNLI) today announced topline results from an analysis…
In this article 7267.T-JP Follow your favorite stocksCREATE FREE ACCOUNT Honda 0 Saloon & Honda 0 SUV prototypes Honda LAS VEGAS —…
While Apple negotiates Indonesia sales ban, another Chinese smartphone maker is entering the country
Pictured here is the Grand Indonesia shopping mall in Jakarta on Friday, Jan. 5, 2024. Bloomberg | Bloomberg | Getty Images BEIJING…
FREMONT, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) — Enovix Corporation (“Enovix”) (Nasdaq: ENVX), a Silicon Valley high-performance battery manufacturing company, today announced the successful completion of Site Acceptance Testing (SAT) for its High Volume Manufacturing (HVM) line at Fab2 in Malaysia. This milestone, achieved in late December, is a critical step toward enabling Fab2 to begin mass production in 2025, supporting the company’s strategy to meet growing global demand for high energy density battery solutions. SAT validates the readiness of…